Precision Biologics Announces Publication Of First-In-Human Phase 1 Clinical Trial With NEO-201

BETHESDA, Md.–(BUSINESS WIRE)–Precision Biologics, Inc. (“Precision”), a clinical-stage immunotherapy and targeted oncology company, announced today the publication of its first in human Phase I clinical trial with its novel monoclonal antibody, NEO-201, targeting the truncated core-1 O-glycan. This trial was performed in patients with refractory solid tumors and has been published in the Journal of Experimental and Clinical Cancer Research.

As discussed in the article, based on the safety and activity of NEO-201, a Phase II study is currently enrolling patients with metastatic Non-Small Cell Lung Cancer (NSCLC), Head and Neck Cancers, Endometrial Cancer and Cervical Cancer, who have already been treated with checkpoint inhibitor therapy (including prior Keytruda). (https://clinicaltrials.gov/ct2/show/NCT03476681). NEO-201 is a unique monoclonal antibody with multiple mechanisms of action. It has been shown previously to kill cancer cells expressing its target. In the Phase I clinical trial, NEO-201 was found to reduce immune suppressive cells that may be responsible in diminishing cancer-killing activity for checkpoint inhibitors like Keytruda. This ongoing Phase 2 trial is testing to see if combining of NEO-201 with Keytruda can reactivate the effectiveness of checkpoint inhibitors when they don’t work alone.

About Precision Biologics

Founded in 2012, Precision Biologics, Inc. is a clinical stage biotechnology corporation focused on developing therapeutic and diagnostic products for the detection and treatment of cancer. The company’s antibody drug candidates and diagnostics are designed to detect and target the tumor with minimal damage to healthy cells. Precision Biologics is uniquely positioned to create innovative therapeutics through the use of proprietary cancer vaccines, several of which have demonstrated success in human trials. By marrying this platform with today’s breakthrough technologies, the company is developing antibody therapeutics that could change the way we detect and treat cancer. For more information on Precision Biologics, please visit http://www.precision-biologics.com/.

Contacts

Media:

RoseMarie Terenzio, [email protected], c: 917-913-7226